Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Trading Cabana -- Ignore unavailable to you. Want to Upgrade?

To: ggersh who wrote (5407)	4/28/2009 2:31:31 PM
From: RockyBalboa	Read Replies (2) \| Respond to of 6370

Prostate cancer vaccine extends survival in study Novel prostate therapy boosts survival in study; first big win for a cancer treatment vaccine * Marilynn Marchione, AP Medical Writer * On Tuesday April 28, 2009, 2:09 pm EDT CHICAGO -- An experimental treatment added four months to the lives of men with advanced prostate cancer, doctors reported Tuesday in a study that tested an entirely new approach to fighting the disease. Related Quotes Symbol Price Change DNDN 11.81 -9.74 Chart for Dendreon Corporation Dendreon Corp.'s Provenge vaccine trains the immune system to fight tumors. It's called a "vaccine" even though it treats disease rather than prevents it. Doctors have been trying to develop such a therapy for decades, and this is the first to meet its goal for improving survival in late-stage testing. "There have been a lot of false starts, but this is a real start," said Dr. Paul Schellhammer, a urologist at Eastern Virginia Medical School in Norfolk, Va., who led the study. Results were reported Tuesday at an American Urological Association conference in Chicago. Seattle-based Dendreon paid for the study, and Schellhammer owns stock in the company. <Dendreon shares fell sharply and then were halted leading up to the release of the data, falling $8.80, or 40.8 percent, to $12.75. The reason was not immediately clear. Four months may not sound like a lot, but it is longer than the three months afforded by Taxotere, the only chemotherapy approved for men in this situation. Doctors hope for even greater benefit if they give the drug earlier in the course of the disease. Dendreon would give no cost estimate for Provenge. It still remains to be seen if side effects will keep Provenge from winning federal Food and Drug Administration approval. Two years ago, the FDA went against its advisers and delayed a decision, asking for more proof of safety and effectiveness.